Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Trial Details

NCT ID
NCT05972135
Phase
PHASE2
Sponsor
SCRI Development Innovations, LLC
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Teclistamab
  • Talquetamab
  • Tocilizumab
  • Oral Dexamethasone
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Newark, Delaware, United States|39.68372,-75.74966
  • Lake Mary, Florida, United States|28.75888,-81.31784

Key Eligibility Criteria

  • Be ≥18 years of age (or the higher legal age in the jurisdiction in which the study is taking place) at the time of informed consent
  • Has documented diagnosis of MM according to the IMWG diagnostic criteria (Rajkumar 2011).
  • Teclistamab or Talquetamab + Tocilizumab: has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody.
  • Teclistamab + Oral Dexamethasone: has received 1 or more prior MM therapies including a PI, IMiD and/or CD38 antibody.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →